Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第9页

Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia. 马来西亚医疗保健专业人员对药物经济学的知识、认知和应用。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-06-01 Epub Date: 2026-04-02 DOI: 10.1080/14737167.2026.2651882

Haarathi Chandriah, Ee Vien Low, Nur Sufiza Ahmad, Azmi Nor Mohd Farez Ahmat, Izzati Mohd Farok, Jacqueline Hui Yi Wong, Weng Hong Fun, Subramaniam Thanimalai, Chin Hui Ng, Nor Haizan Ibrahim, Mohd Rozaini Rosli, Kenneth Lik Chien Lim, Yai Wen Choo

{"title":"Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia.","authors":"Haarathi Chandriah, Ee Vien Low, Nur Sufiza Ahmad, Azmi Nor Mohd Farez Ahmat, Izzati Mohd Farok, Jacqueline Hui Yi Wong, Weng Hong Fun, Subramaniam Thanimalai, Chin Hui Ng, Nor Haizan Ibrahim, Mohd Rozaini Rosli, Kenneth Lik Chien Lim, Yai Wen Choo","doi":"10.1080/14737167.2026.2651882","DOIUrl":"10.1080/14737167.2026.2651882","url":null,"abstract":"Background: Pharmacoeconomics (PE) is essential in optimizing healthcare resource allocation and ensuring cost-effective treatment decisions. Despite its recognized importance, limited evidence exists regarding healthcare professionals' understanding and application of PE in Malaysia. This study assessed the knowledge, perception, and application of PE among healthcare professionals within the Ministry of Health (MOH) Malaysia.Methods: A cross-sectional online survey was conducted among MOH healthcare professionals. The survey captured demographic characteristics, familiarity with PE, self-reported knowledge, perception of its importance, and its application in clinical and formulary decision-making. Descriptive statistics were used to summarize the findings.Results: A total of 754 respondents completed the survey, comprising pharmacists (71.5%), doctors (24.3%) and other healthcare professionals (4.2%). While 63.7% reported familiarity with PE, substantial knowledge gaps were observed, particularly in cost-utility and cost-effectiveness analyses. PE application was most prevalent in budget impact assessments for formulary decisions. Notably, 94.8% of Drug and Therapeutics Committee members recognized the importance of PE in decision-making, and 96.9% supported the need for dedicated personnel with PE competency.Conclusion: PE knowledge and application varied across MOH healthcare professionals, underscoring the need for targeted training and capacity building to strengthen PE competency, ultimately supporting evidence-informed, cost-effective healthcare decision-making in Malaysia.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"621-628"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physicians' preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China. 慢性丙型肝炎治疗中医生对直接作用抗病毒药物的偏好：来自中国离散选择实验的证据

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-23 DOI: 10.1080/14737167.2026.2650162

Yan Li, Junni Du, Chenhui Tian, Aixia Ma, Tiantian Tao, Pingyu Chen

{"title":"Physicians' preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China.","authors":"Yan Li, Junni Du, Chenhui Tian, Aixia Ma, Tiantian Tao, Pingyu Chen","doi":"10.1080/14737167.2026.2650162","DOIUrl":"10.1080/14737167.2026.2650162","url":null,"abstract":"Background: Chronic hepatitis C (CHC) remains a major public health challenge in China. Currently, direct-acting antivirals (DAAs) are the mainstay of clinical treatment. This study employed a discrete choice experiment (DCE) to investigate physicians' preferences regarding DAAs for the treatment of CHC.Methods: A DCE was designed based on the Chinese Guideline for Comprehensive Clinical Evaluation of Drugs and relevant literature, incorporating seven core attributes: safety, efficacy, economy, innovativeness, appropriateness, accessibility, and affordability. Fourteen choice sets were constructed. Physicians' preferences were analyzed using conditional logit models, from which willingness-to-pay (WTP) and relative importance of attributes were derived. Latent class analysis (LCA) was further applied to explore heterogeneity in physicians' preferences.Results: Data were collected from 159 hospitals across 27 provinces in China, with 185 valid questionnaires included. Efficacy emerged as the most important determinant of prescribing preference, followed by affordability and economy, then accessibility, safety, and appropriateness, while innovativeness was not a significant concern. The LCA identified three distinct latent classes, which were significantly associated with demographic variables.Conclusions: In China's healthcare setting, beyond the central importance of efficacy, physicians also place great emphasis on affordability and economic value, with marked heterogeneity in preferences depending on background characteristics.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"557-566"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medication adherence research: expert perspectives on key HEOR trends for 2026. 药物依从性研究：专家对2026年HEOR关键趋势的看法。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-27 DOI: 10.1080/14737167.2026.2650160

Tamas Agh, Bijan Borah, Marcia Vervloet, Mickael Hiligsmann

引用次数: 0

The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005-2019. 2005-2019年丹麦处方药销售变化与死亡率和医院使用率变化的关系

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-05-03 DOI: 10.1080/14737167.2026.2660761

Frank R Lichtenberg

{"title":"The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005-2019.","authors":"Frank R Lichtenberg","doi":"10.1080/14737167.2026.2660761","DOIUrl":"10.1080/14737167.2026.2660761","url":null,"abstract":"Background: The objective of this study is to investigate the relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark during the period 2005-2019.Research design and methods: We analyze the correlation across diseases between changes in sales of drugs used to treat the disease and changes in mortality or hospital utilization from that disease. Two attributes of the drugs used to treat a disease sold each year are constructed and analyzed. The first is the number of drugs sold; the second is the fraction of drugs that were first sold after 1997 (post-1997).Results: The number of years of life lost before ages 85, 75 and 65 and the number of hospital days due to a disease is significantly inversely related to the share of post-1997 drugs used to treat the disease that were sold in previous years.Conclusion: Assuming that the mortality and hospital utilization changes were caused by the changes in prescription drug sales, the 13% estimated reduction in 2016 inpatient curative care expenditure due to the 2002-2013 increase in the share of post-1997 drugs is 2.5 times as large as 2016 expenditure on prescribed medicines first sold after 1997.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"489-499"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of point-of-care A1C tests in the primary care setting of Iran. 伊朗初级保健机构即时护理A1C检测的成本-效果分析

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-26 DOI: 10.1080/14737167.2026.2650163

Abdoreza Mousavi, Mehdi Raadabadi, Ali Darvishi

{"title":"Cost-effectiveness analysis of point-of-care A1C tests in the primary care setting of Iran.","authors":"Abdoreza Mousavi, Mehdi Raadabadi, Ali Darvishi","doi":"10.1080/14737167.2026.2650163","DOIUrl":"10.1080/14737167.2026.2650163","url":null,"abstract":"Background: Given the critical role of timely monitoring in diabetes management, effective and accessible testing strategies are increasingly vital. This study evaluated the cost-effectiveness of point-of-care A1c (POC-A1c) testing compared with traditional laboratory-based A1c testing in primary care settings in Iran.Research design and methods: A lifetime (40 year) Markov model was developed to estimate expected costs (valued in 2023 PPP-adjusted US dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) for the two strategies. Deterministic and probabilistic sensitivity analyses were performed to assess uncertainty in key model parameters.Results: POC-A1C was associated with an incremental cost of US$1,647.76 and a 0.15 QALY gain versus traditional laboratory testing, yielding an ICER of US$10,717.27 per QALY. Consequently, it was cost-effective at a willingness-to-pay threshold equal to Iran's 2023 per capita GDP. Also, based on probabilistic sensitivity analysis, the probability of POC-A1C being cost-effective was 58%.Conclusions: These findings suggest that integrating POC-A1c testing into primary care may represent a valuable strategy for strengthening diabetes management in Iran. While associated with higher direct costs, its potential to improve glycemic control and long-term health outcomes supports consideration by policymakers, particularly in the context of expanding access to timely diabetes monitoring.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"549-556"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevention, artificial intelligence, and mathematics in health economics: a framework for dynamic value modeling under long-term uncertainty. 卫生经济学中的预防、人工智能和数学：长期不确定性下动态价值建模的框架。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-11 DOI: 10.1080/14737167.2026.2642648

Lieke Maas, Ayshe Yaylali, Mickael Hiligsmann

引用次数: 0

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective. 从哥伦比亚医疗保健系统的角度来看，局部晚期或转移性尿路上皮癌患者的新型一线治疗的护理成本和预算影响。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-04-19 DOI: 10.1080/14737167.2026.2660759

Pieralessandro Lasalvia, Paola Jaramillo, Maycos Zapata, Martin Zapata, Leonor González, Verónica Hernández, Juliana Restrepo

{"title":"Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.","authors":"Pieralessandro Lasalvia, Paola Jaramillo, Maycos Zapata, Martin Zapata, Leonor González, Verónica Hernández, Juliana Restrepo","doi":"10.1080/14737167.2026.2660759","DOIUrl":"10.1080/14737167.2026.2660759","url":null,"abstract":"Background: Locally advanced or metastatic urothelial carcinoma (la/mUC) imposes substantial clinical and economic burden. Novel first-line (1L) therapies have expanded treatment options but may significantly increase healthcare expenditures. Economic evidence in Colombia remains limited, warranting cost and budget impact analyses of 1L therapies from the national payer perspective.Research design and methods: Direct healthcare costs of the first year of treatment were estimated for patients with la/mUC starting 1L treatment: chemotherapy (CT) followed by avelumab+best supportive care (BSC); CT+BSC; nivolumab+CT (NIV+CT); and enfortumab vedotin+pembrolizumab (EV+PEM). Efficacy and safety data were obtained from JAVELIN Bladder 100, CheckMate 901, and EV-302. Costs (Colombian pesos; COP, and United States dollars; USD) were estimated for medication acquisition and administration, disease management, severe adverse events (grade ≥3), and subsequent treatments. Drug costs were obtained from SISMED (2024) and Suficiencia. Budget impact compared a base-case scenario (CT+avelumab+BSC) versus an alternative scenario incorporating EV+PEM and NIV+CT.Results: CT+avelumab+BSC was associated with a total annual cost of COP 271,530,508 (US$ 66,693), 66% less than EV+PEM and 24% less than NIV+CT. Budget impact analysis showed an increase of COP 160,067,748,642 (US$ 39.32 million) (+42.8%).Conclusions: CT+avelumab+BSC had the lowest annual cost, suggesting it is affordable versus EV+PEM and NIV+CT.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"477-488"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-12 DOI: 10.1080/14737167.2026.2642658

Yedhu Harikumar, Muthumeenakshi Muralikrishna, Prakasam Muralikrishna, Andrew Adewale Alola

{"title":"Climate-related risk and pharmaceutical market dynamics in India and USA: evidence from transfer entropy, BEKK GARCH, and coherence wavelet.","authors":"Yedhu Harikumar, Muthumeenakshi Muralikrishna, Prakasam Muralikrishna, Andrew Adewale Alola","doi":"10.1080/14737167.2026.2642658","DOIUrl":"10.1080/14737167.2026.2642658","url":null,"abstract":"Background: Greenhouse gas emissions, especially the atmospheric trapping of carbon dioxide (CO2), are widely linked to increased weather variability, thereby affecting other aspects of human activity and nature. The increased occurrence of intense rainfall, heat waves, flooding, and droughts worsens the volatility of financial markets.Research design and methods: The present study aims to investigate the cross-impacts of climate change and pharmaceutical sector activities, particularly in the United States (US) and India. Climate risks are predominant in emerging economies such as India, which lack sufficient resources for climate change mitigation and adaptation. In this context, we employ transfer entropy, BEKK GARCH (Baba, Engle, Kraft, and Kroner Generalized Autoregressive Conditional Heteroskedasticity), and coherence wavelet approaches to examine the relationship between the two aspects.Results: India's pharmaceutical index contributes more to climate risk. Interestingly, US pharmaceutical market co-movements with climate risks are high despite low volatility spillover. This suggests developed nations like the US possess superior resources to manage climate risks compared to developing economies like India.Conclusions: While this outcome is limited to the contexts of India and the US, it offers insights to decision-makers, investors, and relevant portfolio managers on the vulnerability of essential sectors to climate-related risks.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"523-535"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Duration changes and decision-making in DCE_TTO: evidence from SF-6Dv2. DCETTO病程变化和决策：来自SF-6Dv2的证据。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-10 DOI: 10.1080/14737167.2026.2642655

Hosein Ameri, Thomas G Poder

{"title":"Duration changes and decision-making in DCETTO: evidence from SF-6Dv2.","authors":"Hosein Ameri, Thomas G Poder","doi":"10.1080/14737167.2026.2642655","DOIUrl":"10.1080/14737167.2026.2642655","url":null,"abstract":"Background: This study investigated the impact of changes in health state duration in a discrete choice experiment where duration is an attribute (DCETTO).Methods: A sample of the general population in Quebec, Canada, completed DCETTO in two phases using SF-6Dv2. In the first phase (DCEoriginal), participants were presented with binary choice sets, each containing two health states and associated durations. In the second phase (DCEchanged), they completed the same choice sets as before, but with modified durations. Adjustments were made based on participants' initial responses. Durations were 1, 4, 7, 10, 14, and 20 years. McNemar's Test was used to evaluate the change in respondents' choices before and after the duration modification.Results: A total of 411 participants were included. Significant increases in duration of the option not chosen (by a factor of two or more) led it to become the preferred option (p < 0.05). A decrease in the duration of the option chosen could still lead to its acceptance. Overall, participants showed a strong anchoring effect of their initial choice, while changes in duration had a moderate positive effect on the likelihood of switching choices.Conclusions: Findings highlight non-linear effects of time on preferences and have important implications for the design of DCETTO studies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"501-510"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Net benefits of investing in pulse oximetry and oxygen for childhood pneumonia in high burden countries. 在高负担国家投资脉搏血氧仪和供氧治疗儿童肺炎的净效益。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-27 DOI: 10.1080/14737167.2026.2650165

Tim Colbourn, Carina King

引用次数: 0